Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCardia, Inc.BCDA;BCDAW · Entity 7752 | Director | July 26, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCardia, Inc.
Report date July 26, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,681 |
Reported balance
After 2019-07-26 transaction · row 1
1 source rowRow 1 · 2019-07-26 · Exercise / conversion · Acquired 3,594 · Balance 15,681 F1: Represents the conversion upon vesting of RSUs into common stock. On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019) that were previously reported on Table II of Form 4, which form was filed with the SEC on September 26, 2018. F2: The converted RSU corresponds to a 1:1 common stock issuance. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-26 · Exercise / conversion · Disposed 3,594 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019), which vested on July 26, 2019. The common stock into which such vested RSUs converted on July 26, 2019 is reported on Table I of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of RSUs into common stock. On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019) that were previously reported on Table II of Form 4, which form was filed with the SEC on September 26, 2018.
F2: The converted RSU corresponds to a 1:1 common stock issuance.
F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4: On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019), which vested on July 26, 2019. The common stock into which such vested RSUs converted on July 26, 2019 is reported on Table I of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2019 Filed Aug 23, 2019 10:31 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Exercise / conversionRestricted Stock Units · Derivative | 3,594 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-017333 · rdgdoc.xml · derivative · entry 2 Quertermous Thomas · CIK 0001647524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019), which vested on July 26, 2019. The common stock into which such vested RSUs converted on July 26, 2019 is reported on Table I of this Form 4. F4 · derivative.expiration_date: On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019), which vested on July 26, 2019. The common stock into which such vested RSUs converted on July 26, 2019 is reported on Table I of this Form 4. Read SEC document |
| July 26, 2019 Filed Aug 23, 2019 10:31 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Exercise / conversionCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-017333 · rdgdoc.xml · nonDerivative · entry 1 Quertermous Thomas · CIK 0001647524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of RSUs into common stock. On July 26, 2018, the reporting person was granted 32,353 RSUs (3,594 after the 1-for-9 reverse split effective May 7, 2019) that were previously reported on Table II of Form 4, which form was filed with the SEC on September 26, 2018. F2 · price: The converted RSU corresponds to a 1:1 common stock issuance. Read SEC document |
| July 26, 2018 Filed Sep 27, 2018 01:17 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantRestricted Stock Units · Derivative | 32,353 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-017510 · rdgdoc.xml · derivative · entry 1 Quertermous Thomas · CIK 0001647524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,353 Underlying: Common Stock · 32,353 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest as to one hundred percent of the shares on July 26, 2019, subject to the Reporting Person continuing as a service provider through such date. Vested shares will be delivered to the Reporting Person on July 26, 2019. F2 · derivative.expiration_date: The restricted stock units vest as to one hundred percent of the shares on July 26, 2019, subject to the Reporting Person continuing as a service provider through such date. Vested shares will be delivered to the Reporting Person on July 26, 2019. Read SEC document |
| June 15, 2017 Filed Aug 25, 2017 21:46 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantDirector Stock Option (right to buy) · Derivative | 156,583 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-17-015344 · rdgdoc.xml · derivative · entry 1 Quertermous Thomas · CIK 0001647524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,583 Underlying: Common Stock · 156,583 shares Expires 2027-06-15 F1 · derivative.exercise_date: One hundred percent of the shares subject to the option vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 23:39 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantDirector Stock Option (right to buy) · Derivative | 267,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001437749-17-000792 · rdgdoc.xml · derivative · entry 1 Quertermous Thomas · CIK 0001647524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,000 Underlying: Common Stock · 267,000 shares Expires 2027-01-13 F1 · derivative.exercise_date: The option vests and becomes exercisable as to one-third of the shares on January 13, 2018 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.